
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for ELV and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ELV and 80,000+ other tickers.
See exactly how ELV's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ELV and 80,000+ other tickers.
Operating as a major health benefits organization, Elevance Health Inc. commits to guiding consumers, families, and communities across their entire health and wellness path. It facilitates access to vital care, assistance, and tools designed to enable healthier living for approximately 118 million individuals. The company's comprehensive offerings span medical, digital, pharmaceutical, behavioral health, clinical, and other care solutions. Founded in 1944 and based in Indianapolis, Indiana, this entity adopted its current name, Elevance Health Inc., in June 2022, having previously operated as Anthem, Inc.

US equities advanced during Q2, supported by another quarter of better-than-expected corporate earnings and continued enthusiasm for companies benefiting from artificial intelligence-related investment. Our bottom five contributors to return in Q2 were Accenture, CME Group, Salesforce, Boston Scientific and EOG Resources. Our top five contributors to return in Q2 were Texas Instruments, Lam Research, NXP Semiconductors, Elevance Health and Alphabet.

The purchase of 1,000 shares at $366.05 per share represents a total capital commitment of $366,050. This transaction increased the director's total direct equity position by 10% relative to his pre-trade holdings.

Elevance Health (NYSE: ELV) raised its 2026 adjusted earnings outlook after second-quarter results came in ahead of management's expectations, citing favorable benefit expense performance, disciplined cost management and improving execution across several major business lines. President and CEO Gail Boudreaux said the company now expects 2026 adjusted diluted earnings per share of at least $27. Chief

The CEO executed an open-market purchase of 2,725 shares, representing a capital commitment of ~$1.0 million. The transaction increased the insider's total equity holdings by 2% of the previously held position.

Your Medicare Advantage plan stays active on paper, but the hospital you have used for decades can quietly vanish from your network before your next appointment, and the protections meant to help you come with conditions most patients never see coming.